Clinical and Applied Thrombosis/Hemostasis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAEGTRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alsayegh, F.
Right arrow Articles by Mousa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alsayegh, F., Dr
Right arrow Articles by Mousa, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
First published on December 26, 2007
Clinical and Applied Thrombosis/Hemostasis 2007, doi:10.1177/1076029607308863
© 2007 SAGE Publications

Article

Use of Recombinant Activated Factor VII to Arrest Uncontrolled Bleeding: A Case Series

Faisal Alsayegh Dr, MD, Aisha Fakeir, MD, Salah Alhumood, MD, Kefaya Abdumalek, MD, Hatem Matar, MD, Isaac Samaul, MD, Narayanan Nampoory, MD, Housam Kabalawi, MD, and Shaker Mousa*

Albany College of Pharmacy

* To whom correspondence should be addressed. E-mail: mousas{at}acp.edu.


  Abstract
A retrospective analysis is described to assess the effects of using recombinant activated factor VII to control bleeding in a series of patients who had failed to respond to conventional hemostatic measures. In all, 18 patients (aged 16-65 years) with a range of conditions resulting in bleeding refractory to conventional methods of control were treated with recombinant activated factor VII (60-120 µg/kg; 1-4 doses). The effects of recombinant activated factor VII on bleeding were noted together with the patients’ transfusion requirements and hematological parameters. Administration of recombinant activated factor VII successfully stopped bleeding in 17 of the 18 patients. Therapy with recombinant activated factor VII significantly decreased transfusion requirements for packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate compared with pretreatment values along with significant improvement in hemostasis. In various serious bleeding situations, treatment with recombinant activated factor VII may effectively arrest bleeding, which has remained refractory to conventional methods of control.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?